DS
Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
---|---|---|---|---|---|---|---|
Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder | Molecular therapy. Nucleic acids | 2025 | 7 | 2 | |||
Cortical neurons obtained from patient-derived iPSCs with GNAO1 p.G203R variant show altered differentiation and functional properties | Heliyon | 2024 | 207 | 43 | |||
Zinc for GNAO1 encephalopathy : preclinical profiling and a clinical case | Med | 2024 | 62 | 56 | |||
Pediatric GNAO1 encephalopathies: from molecular etiology of the disease to drug discovery | Neural Regeneration Research | 2023 | 81 | 64 | |||
Cells of the tumor microenvironment speak the Wnt language | Trends in molecular medicine | 2023 | 111 | 4 | |||
Chlorin endogenous to the north pacific brittle star ophiura sarsii for photodynamic therapy applications in breast cancer and glioblastoma models | Biomedicines | 2022 | 472 | 115 | |||
Mouse models characterize GNAO1 encephalopathy as a neurodevelopmental disorder leading to motor anomalies: from a severe G203R to a milder C215Y mutation | Acta neuropathologica communications | 2022 | 241 | 114 | |||
Marine natural products from the russian pacific as sources of drugs for neurodegenerative diseases | Marine drugs | 2022 | 129 | 119 | |||
Pediatric encephalopathy: cinical, biochemical and cellular insights into the role of Gln52 of GNAO1 and GNAI1 for the dominant disease | Cells | 2021 | 369 | 141 |